ctDNA-Informed Management of Early-Stage Rectal Cancer

Part of paid clinical trials in Sacramento, California.

Sponsor: University of California, Davis
Study ID: NCT07209215
Phase: PHASE2
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Early-stage Rectal Cancer
Locally Advanced Rectal Adenocarcinoma
Rectal Adenocarcinoma
Rectal Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) — DRUG
Use of Signatera Genome ultra-sensitive ctDNA blood test post-total neoadjuvant therapy (TNT) for ctDNA-informed treatment management of early-stage rectal cancer.

Study Details

This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.